The startup is focused on developing proprietary medicines to treat diarrhea caused by diseases such as cholera and microvillus inclusion disease. By conducting targeted research, the company aims to enhance access to effective treatments while lowering healthcare delivery costs.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diarrheal diseases, including cholera and microvillus inclusion disease (MVID), lack effective treatments, leading to high morbidity and mortality rates, especially in vulnerable populations. Current treatments often fail to address the underlying causes of diarrhea, focusing instead on symptom management and supportive care. This results in prolonged illness, increased healthcare costs, and reduced quality of life for affected individuals.
Solution
Vanessa Biotech is developing proprietary medicines to address the root causes of diarrheal diseases, focusing on restoring intestinal function and reducing dependence on supportive therapies. Their lead product, Shylicine™, is an investigational drug for MVID designed to promote normal growth of immature intestinal cells and restore fluid and nutrient absorption, potentially eliminating the need for intravenous nutrition or bowel transplants. Additionally, Vanessa Biotech is developing HunaZine™ to neutralize the cholera toxin and combat lethal diarrhea caused by cholera. The company also offers GMP pharmaceutical contract manufacturing services, ensuring quality and agility in drug production.
Target Audience
The primary target audience includes patients suffering from diarrheal diseases such as cholera and MVID, their caregivers, and healthcare providers specializing in gastroenterology and rare diseases. Vanessa Biotech also serves pharmaceutical companies seeking contract manufacturing services.
Features
- Shylicine™: A novel cocktail designed to reverse the imbalance of intestinal secretion and absorption caused by microvillus inclusion disease (MVID). Currently in Phase 2 clinical trials with orphan drug designation.
- HunaZine™: Developed to neutralize lethal diarrhea induced by the cholera toxin; currently undergoing Phase 2 clinical trials in Bangladesh.
- GMP Pharmaceutical Contract Manufacturing: Full-scale manufacturing services with a focus on quality and agility, catering to liquid, solid, and semi-solid pharmaceutical forms.
- Research and Development: Focus on identifying and commercializing innovative solutions for overlooked healthcare markets, particularly in gastroenterological conditions.